Press release
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":" FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences:\n\n\n\nStifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 8:40 a.m. EST\n\n\n\nJefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at 1:30 p.m. GMT\n\n\n\nThe live audio webcast of each presentation will be accessible on the Investors section of the Company’s website at www.ir.kalvista.com/event-calendar. An archived replay will be available approximately two hours after the completion of the events.\n\n\nAbout KalVista Pharmaceuticals, Inc.\nKalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY®—the first and only oral on-demand treatment for hereditary angioedema (HAE)—and continues to work closely with the global HAE community to improve treatment and care for this disease around the world. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20251105630013/en/\n\nInvestors:\nRyan Baker\nHead, Investor Relations\n(617) 771-5001\[email protected]\n\nMedia:\nMolly Cameron\nDirector, Corporate Communications\n(857) 356-0164\[email protected]\n\n\nSource: KalVista Pharmaceuticals, Inc.","length":4600,"tagName":"div"}]